Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(13%)
Results Posted
20%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
3
38%
Ph phase_1
4
50%
Ph early_phase_1
1
13%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (12.5%)
Phase 14 (50.0%)
Phase 23 (37.5%)

Trials by Status

recruiting113%
terminated113%
unknown113%
completed563%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

NCT05799144
completedphase_1

Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B

NCT00988767
unknownearly_phase_1

DNA Vaccination Against Neuroblastoma

NCT04049864
completedphase_1

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
completedphase_2

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

NCT01706458
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05799144Phase 2

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting
NCT00988767Phase 1

Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B

Completed
NCT04049864Early Phase 1

DNA Vaccination Against Neuroblastoma

Unknown
NCT00801697Phase 1

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Completed
NCT01706458Phase 2

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Completed
NCT01493154Phase 1

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Terminated
NCT01498718Phase 1

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Completed
NCT01705223Phase 2

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8